International Medical Services
Outcome Research
The UCT Mainz has a long-standing expertise in cancer epidemiology and outcome research with a specific focus on the identification of risk factors for cancer incidence and mortality and on late effects after cancer treatment. Research on late effects comprises analyses of survival, occurrence of secondary malignancies and cardiovascular late effects, quality of life, psychosocial rehabilitation, and cancer survivorship.
Future aims include the integration of quality of life measurements with patient-reported outcomes as a standard into all phase III cancer clinical trials at the UCT Mainz and the improvement of the infrastructure for high-dimensional data analyses with the formation of a data hub at the UCT Mainz. In addition, we will establish a collaboration with the Sports Science Faculty to investigate the association between physical activity and immune response.
Research Groups
Most significant publications since 2019
Harbeck, N., Kates, R., Schinköthe, T., Schumacher, J., Wuerstlein, R., Degenhardt, T., Lüftner, D., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Fasching, P.A., Schmidt, M. 2023. Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy. Cancer Treat Rev. 121, 102631.
Eichler, M., Distler, U., Nasrullah, U., Krishnan, A., Kaulich, M., Husnjak, K., Eberhardt, W., Rajalingam, K., Tenzer, S., Pfeilschifter, J., Imre, G. 2022. The caspase-2 substrate p54nrb exhibits a multifaceted role in tumor cell death susceptibility via gene regulatory functions. Cell Death Dis. 13(4), 386.
Galle, P.R., Finn, R.S., Qin, S., Ikeda, M., Zhu, A.X., Kim, T.Y., Kudo, M., Breder, V., Merle, P., Kaseb, A., Li, D., Mulla, S., Verret, W., Xu, D.Z., Hernandez, S., Ding, B., Liu, J., Huang, C., Lim, H.Y., Cheng, A.L., Ducreux, M. 2021. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 22(7), 991-1001.
- Renovanz, M., Hickmann, A.K., Nadji-Ohl, M., Keric, N., Weimann, E., Wirtz, C.R., Singer, S., Ringel, F., Coburger, J. 2020. Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma-results of a multicenter study. Support Care Cancer. 28(11), 5165-5175.
- Hechtner, M., Eichler, M., Wehler, B., Buhl, R., Sebastian, M., Stratmann, J., Schmidberger, H., Gohrbandt, B., Peuser, J., Kortsik, C., Nestle, U., Wiesemann, S., Wirtz, H., Wehler, T., Bals, R., Blettner, M., Singer, S. 2019. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. J Thorac Oncol. 14(3), 420-435.
